Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity.
Zimmerman O, Altman Doss AM, Ying B, Liang CY, Mackin SR, Davis-Adams HG, Adams LJ, VanBlargan LA, Chen RE, Scheaffer SM, Desai P, Raju S, Mantia TL, O'Shaughnessy CC, Monroy JM, Wedner HJ, Rigell CJ, Kau AL, Dy TB, Ren Z, Turner JS, O'Halloran JA, Presti RM, Kendall PL, Fremont DH, Ellebedy AH, Diamond MS.
Zimmerman O, et al. Among authors: o halloran ja.
JCI Insight. 2024 Feb 8;9(3):e176359. doi: 10.1172/jci.insight.176359.
JCI Insight. 2024.
PMID: 38175703
Free PMC article.
Anti-spike antibody titers and neutralizing activity against SARS-CoV-2 WA1/2020 D614G increased gradually after the pandemic started and reached levels comparable to vaccinated healthy donors 18 months after the diagnosis of the first COVID-19 case in the United States in …
Anti-spike antibody titers and neutralizing activity against SARS-CoV-2 WA1/2020 D614G increased gradually after the pandemic started and re …